Business
EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter, best quarterly performance ever for the Group
Revenue up 11.7% in the third quarter Best quarterly performance ever for the Group Group’s revenue +11.7% in the third quarter at constant exchange rates1, +8.8% in the nine monthsWearables major boost, enlarging the portfolio with a strong pipeline of product innovationVision care and sunglasses growing 5% at constant exchange rates1 and perimeterNorth America and EMEA up double digits in both PS and DTC channelsStellest supported by strong clinical results, “de novo” fully approved by FDA, in
About this update from Essilorluxottica Sa
[{"type":"image","alt":"EssilorLuxottica","displaySize":"","headline":null,"caption":"EssilorLuxottica","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/917e4a586fd01b9ae482d2ec9b2b8eb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NyPhKYW6.EAnTgAoI_btNQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/917e4a586fd01b9ae482d2ec9b2b8eb5","width":300,"height":33}},"lazy":false},{"type":"text","content":"Revenue up 11.7% in the third quarter","length":37,"tagName":"p"},{"type":"text","content":"Best quarterly performance ever for the Group","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Group’s revenue +11.7% in the third quarter at constant exchange rates1, +8.8% in the nine months","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Wearables major boost, enlarging the portfolio with a strong pipeline of product innovation","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Vision care and sunglasses growing 5% at constant exchange rates1 and perimeter","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"North America and EMEA up double digits in both PS and DTC channels","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Stellest supported by strong clinical results, “de novo” fully approved by FDA, in the US market from October","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"RetinAI acquisition announced yesterday. Optegra closed, to be consolidated as of October, 1","length":92,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":535,"olType":false},{"type":"text","content":"Paris, France (October 16, 2025 - 6:00 pm) – EssilorLuxottica announced today that consolidated revenue for the third quarter of 2025 reached Euro 6,867 million, representing a year-on-year increase of 11.7% at constant exchange rates1 compared to the third quarter of 2024 (+6.7% at current exchange rates).","length":308,"tagName":"p"},{"type":"text","content":"Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO at EssilorLuxottica commented: “Achieving our best quarter ever since the creation of the Group, we mark a milestone that speaks to the strength of our vision and the ability of our young and strong manageme...